ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

Clinical trial NCT07504796 · RECRUITING

Trial details

NCT number: NCT07504796
Sponsor: NYU Langone Health
Status: RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Metastatic Melanoma Advanced Melanoma

Start date: 2026-04-13
Primary completion: 2029-05-01
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.